

IDERA PHARMACEUTICALS, INC.  
Form 8-K  
March 23, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 17, 2015**

**Idera Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**001-31918**  
**(Commission**  
**File Number)**

**04-3072298**  
**(IRS Employer**  
**Identification No.)**

**167 Sidney Street**

**02139**

Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 8-K

**Cambridge, Massachusetts**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (617) 679-5500**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 17, 2015, Louis Brenner, M.D. resigned his positions as Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Idera Pharmaceuticals, Inc.**

Date: March 23, 2015

By: /s/ Louis J. Arcudi, III  
Louis J. Arcudi, III  
*Senior Vice President of Operations, Chief Financial  
Officer and Treasurer*